TWI704918B - 含有細胞周期蛋白抑制劑的藥物製劑及其製備方法 - Google Patents
含有細胞周期蛋白抑制劑的藥物製劑及其製備方法 Download PDFInfo
- Publication number
- TWI704918B TWI704918B TW104136656A TW104136656A TWI704918B TW I704918 B TWI704918 B TW I704918B TW 104136656 A TW104136656 A TW 104136656A TW 104136656 A TW104136656 A TW 104136656A TW I704918 B TWI704918 B TW I704918B
- Authority
- TW
- Taiwan
- Prior art keywords
- pharmaceutical composition
- item
- patent application
- scope
- optionally
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 239000000825 pharmaceutical preparation Substances 0.000 title abstract description 9
- 229940122560 Cyclin inhibitor Drugs 0.000 title abstract 2
- 239000002775 capsule Substances 0.000 claims abstract description 22
- 150000001875 compounds Chemical class 0.000 claims abstract description 21
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 4
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 42
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 23
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 12
- 235000019359 magnesium stearate Nutrition 0.000 claims description 11
- 229920002472 Starch Polymers 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 239000008107 starch Substances 0.000 claims description 10
- 229940032147 starch Drugs 0.000 claims description 10
- 235000019698 starch Nutrition 0.000 claims description 10
- 239000008187 granular material Substances 0.000 claims description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 8
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- 239000007888 film coating Substances 0.000 claims description 8
- 238000009501 film coating Methods 0.000 claims description 8
- 239000008101 lactose Substances 0.000 claims description 8
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 8
- 238000011049 filling Methods 0.000 claims description 7
- 239000000314 lubricant Substances 0.000 claims description 7
- 239000011230 binding agent Substances 0.000 claims description 5
- 239000007884 disintegrant Substances 0.000 claims description 5
- 238000005469 granulation Methods 0.000 claims description 5
- 230000003179 granulation Effects 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- 239000008119 colloidal silica Substances 0.000 claims description 4
- 229960000913 crospovidone Drugs 0.000 claims description 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 4
- 229940049654 glyceryl behenate Drugs 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 4
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 4
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 4
- 229940069328 povidone Drugs 0.000 claims description 4
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 4
- 239000008117 stearic acid Substances 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 3
- 229930195725 Mannitol Natural products 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 238000007908 dry granulation Methods 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 3
- 229960003943 hypromellose Drugs 0.000 claims description 3
- 239000000594 mannitol Substances 0.000 claims description 3
- 235000010355 mannitol Nutrition 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 238000005550 wet granulation Methods 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 2
- 235000010216 calcium carbonate Nutrition 0.000 claims description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 2
- 235000011132 calcium sulphate Nutrition 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 229960001375 lactose Drugs 0.000 claims description 2
- 229960001855 mannitol Drugs 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 229960002900 methylcellulose Drugs 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 229920000053 polysorbate 80 Polymers 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 239000002002 slurry Substances 0.000 claims description 2
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 2
- 239000008109 sodium starch glycolate Substances 0.000 claims description 2
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 229940075529 glyceryl stearate Drugs 0.000 claims 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 claims 1
- 229920001993 poloxamer 188 Polymers 0.000 claims 1
- 229940044519 poloxamer 188 Drugs 0.000 claims 1
- 238000004090 dissolution Methods 0.000 abstract description 12
- 239000004480 active ingredient Substances 0.000 abstract description 2
- 239000002552 dosage form Substances 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- AHJRHEGDXFFMBM-UHFFFAOYSA-N palbociclib Chemical compound N1=C2N(C3CCCC3)C(=O)C(C(=O)C)=C(C)C2=CN=C1NC(N=C1)=CC=C1N1CCNCC1 AHJRHEGDXFFMBM-UHFFFAOYSA-N 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 239000008186 active pharmaceutical agent Substances 0.000 description 5
- 238000003825 pressing Methods 0.000 description 5
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 4
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 4
- 230000004584 weight gain Effects 0.000 description 4
- 235000019786 weight gain Nutrition 0.000 description 4
- -1 and more preferably Substances 0.000 description 3
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 229940124297 CDK 4/6 inhibitor Drugs 0.000 description 2
- 101000715943 Caenorhabditis elegans Cyclin-dependent kinase 4 homolog Proteins 0.000 description 2
- 102000016736 Cyclin Human genes 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 0 CC(C1=C(C)c2cnc(Nc(nc3)ccc3N3CCNCC3)nc2N(C2C*CCC2)C1=O)=* Chemical compound CC(C1=C(C)c2cnc(Nc(nc3)ccc3N3CCNCC3)nc2N(C2C*CCC2)C1=O)=* 0.000 description 1
- 108091007914 CDKs Proteins 0.000 description 1
- 102000003910 Cyclin D Human genes 0.000 description 1
- 108090000259 Cyclin D Proteins 0.000 description 1
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 239000004605 External Lubricant Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000035327 Oestrogen receptor positive breast cancer Diseases 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 102100025803 Progesterone receptor Human genes 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000018486 cell cycle phase Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
本發明涉及一種以6-乙醯基-8-環戊基-5-甲基-2-(5-呱
-1-基-吡啶-2-基胺基)-8H-吡啶并[2,3-d]嘧啶-7-酮或其鹽為活性成分的藥物製劑，該等鹽包括鹽酸鹽、羥乙基磺酸鹽，該等藥物劑型包括片劑、膠囊劑。該等劑型均具有良好的穩定性以及優異的溶出行為。
Description
本發明屬於藥物製劑領域，具體涉及用於細胞周期蛋白抑制劑的藥物製劑及其製備方法。
細胞周期蛋白依賴性激酶(CDK)共有13個成員，都屬絲胺酸/蘇胺酸蛋白激酶家族，依賴與細胞周期蛋白(cyclin)的結合，促進細胞周期時相轉變，啟動DNA合成以及調控細胞轉錄等關鍵功能。
CDKs在所有細胞包括健康和腫瘤細胞的增殖與死亡中所起的關鍵作用，廣泛的CDK抑制劑，尤其是針對未經過基因篩選的患者很難展現較高的治療窗口。劑量大了毒性太高，而小了又沒有藥效。所以選擇性地抑制部分CDK就變得格外重要。當然因為大部分CDK亞型具有相對近似的化學結構，如何提高CDK抑制劑的選擇性又是另外一個挑戰。
CDK4/6作為抗腫瘤標靶的優勢在於：①CDK4/6的抑制劑不表現出“泛-CDK抑制劑”的細胞毒
性，如骨髓抑制和腸道反應；②細胞cyclin D水準升高或者P161NK4a失活，能夠增加細胞對藥物的敏感性，腫瘤細胞相對於正常細胞存在上述現象，所以一定程度上增加了藥物的靶向性。
式I化合物是一種靶向性CDK4/6抑制劑，能夠選擇性抑制細胞周期蛋白依賴性激酶4和6(CDK4/6)，恢復細胞周期控制，阻斷腫瘤細胞增殖。其作用於MDA-MB-435乳腺癌細胞，能有效降低Rb在Ser780和Ser795位點磷酸化，IC50分別為66nM和63nM。
乳腺癌是女性最常見的惡性腫瘤之一，具有發病率高，頗具侵襲性，但病程進展緩慢。據國際癌症研究中心公佈的資料顯示，2012年全球約有167萬新發病例，占所有癌症的25%。美國國家癌症中心流行病學調查和最終結果(SEER)統計，2013年美國估計性乳腺癌發病率為123.8/10萬人，2005至2009年亞裔人群女性乳腺癌發病率為94.5/10萬人；我國無官方資料，據估計我國有60%至70%的乳腺癌患者雌激素或孕激素受體呈陽性，推算我國雌激素受體陽性乳腺癌2005至2009年發病率為56.7至66.15/10萬人。Thomson預測，本品上市後銷售額將大幅上升，2019年銷售額將達20.27億美元。
本發明的目的在於提供一種含有6-乙醯基-8-環戊基-5-甲基-2-(5-呱
-1-基-吡啶-2-基胺基)-8H-吡啶并[2,3-d]嘧啶-7-酮及鹽的藥物製劑及其製備方法。
本發明的技術方案是藉由下列方式實現的：
藥物組合物，其包括式I化合物或其鹽，以及藥學上可接受的賦形劑作為載體，該等鹽型包括鹽酸鹽、羥乙基磺酸鹽。
較佳的，式I化合物占該等組合物重量的10%至80%，較佳係15至60%，進一步較佳係20至40%。
較佳的，該等組合物包括式I化合物或其鹽及賦形劑，該等賦形劑包括崩解劑、稀釋劑、黏合劑、表面活性劑、潤滑劑中一種或多種，較佳的，各組分重量比如下：
任選的，該等組合物中還可以包含矯味劑、著色劑或包衣材料，最佳的，上述各組分的重量百分比之和為100%。
進一步較佳的，該等的藥物製劑，各組分的重量百分比如下：
任選的，該等組合物中還可以包含矯味劑、著色劑或包衣材料，最佳的，上述各組分的重量百分比之和為100%。
更佳的，該等的藥物製劑，各組分的重量百分比如下：
較佳的，該等稀釋劑選自澱粉、糖粉、糊精、乳糖、預膠化澱粉、磷酸氫鈣、硫酸鈣、碳酸鈣、甘露醇、山梨醇、微晶纖維素的至少一種，進一步較佳的，該等稀釋劑選自乳糖、微晶纖維素、澱粉或甘露醇中的至少一種，更佳的，該等稀釋劑選自乳糖和微晶纖維素。
較佳的，該等乳糖和微晶纖維素的重量比為1：2至2：1，較佳係1：1。
較佳的，該等黏合劑選自澱粉漿、羥丙甲纖維素、羥丙纖維素、聚維酮、甲基纖維素、羧甲基纖維素鈉、聚乙二醇的至少一種，更佳的，該等稀釋劑選自羥
丙基纖維素或聚維酮的至少一種。
較佳的，該等崩解劑選自交聯羧甲基纖維素鈉、羧甲基澱粉鈉、交聯聚維酮、乾澱粉、低取代羥丙基纖維素的至少一種，更佳的，該等崩解劑選自交聯聚維酮、羧甲澱粉鈉、交聯羧甲基纖維素鈉中的至少一種。
較佳的，該等潤滑劑選自硬脂酸鎂、硬脂酸、硬脂富馬酸鈉、山崳酸甘油酯、膠態二氧化矽、滑石粉、二氧化矽中的至少一種，更佳的，該等潤滑劑選自硬脂酸、山崳酸甘油酯、膠態二氧化矽中的至少一種。
較佳的，該等表面活性劑為十二烷基硫酸鈉、吐溫80和泊洛沙姆，更佳的，該等表面活性劑為十二烷基硫酸鈉。
另一方面，本發明提供了製備式(I)化合物或其鹽的製備方法，該等製備工藝包括濕法製粒、乾法製粒、直接混合等工藝，該等劑型包括片劑、膠囊。
較佳的，該等組合物是藉由濕法製粒完成的，該等方法包括以下步驟：(1)在濕法混合製粒機中預混合式I化合物或其鹽與部分潤滑劑，獲得預混合物；(2)添加製粒液體，較佳的，該等製粒液體為水，將步驟(1)的預混合物製粒；(3)在流化床乾燥器或乾燥箱中乾燥步驟(2)的顆粒；(4)任選的，乾燥篩分步驟(3)的乾燥的顆粒；(5)混合步驟(4)的乾燥的顆粒與剩餘賦形劑，獲得最終
混合物；(6)任選的，藉由合適的膠囊灌裝機灌裝上述步驟(5)的混合物，製備膠囊劑；(7)任選的，藉由在合適的壓片機上壓製上述步驟(5)的混合物，將其壓片，從而製得片芯；(8)任選的，用膜包衣對步驟(7)的片芯進行薄膜包衣。
較佳的，該等組合物是藉由乾法製粒完成的，該等方法包括以下步驟：(1)在料斗混合機中混合該等式I化合物或其鹽和包括黏合劑在內的大多數賦形劑，獲得預混合物；(2)在合適的滾筒壓製機中壓實步驟(1)的混合物；(3)藉由合適的研磨或篩分步驟，將步驟(2)期間獲得的帶狀物碎成顆粒；(4)任選的，在混合機中混合步驟(3)和剩餘賦形劑，獲得最終混合物；(5)任選的，藉由合適的膠囊灌裝機灌裝上述步驟(4)的混合物，製備膠囊劑；(6)任選的，藉由在合適的壓片機上壓製上述步驟(4)的混合物，將其壓片，從而製得片芯；(7)任選的，用膜包衣對步驟(6)的片芯進行薄膜包衣。
本發明提供了一種穩定的，適合醫藥應用的6-乙醯基-8-環戊基-5-甲基-2-(5-呱
-1-基-吡啶-2-基胺基)-8H-吡啶并[2,3-d]嘧啶-7-酮及鹽的藥物製劑，該藥物製劑具有優異的溶出行為和好的穩定性，符合臨床應用需
求，能夠使活性成分實現良好的體內生物利用度。
下面將結合具體實施例，對本發明的實施方案進行詳細描述。下面實施例僅用於說明本發明，而不應視為限定本發明的範圍。
將上述1000片處方量式I化合物和除硬脂酸鎂外其他賦形劑投入料斗混合機混勻，加潤濕劑潤濕製粒，45℃流化床乾燥10min，1.0mm篩整粒，加硬脂酸鎂總混10min，中控含量，灌裝膠囊。或壓製成片。
各處方在0.1mol/L HCl中溶出度，詳見下表。
將上述1000片處方量式I化合物和除硬脂酸鎂外其他賦形劑投入料斗混合機混勻，採用滾筒壓製機壓成帶狀物，將帶狀物碎成顆粒，加硬脂酸鎂總混10min，中控含量，灌裝膠囊。或壓製成片。
將上述1000片處方量式I化合物和賦形劑投入料斗
混合機混勻，中控含量，灌裝膠囊。或壓製成片。
將上述1000片處方量API和除硬脂酸鎂外其他賦形劑投入料斗混合機混勻，加潤濕劑潤濕製粒，流化床45℃乾燥10min，1.0mm篩整粒，加硬脂酸鎂總混10min，中控含量，灌裝膠囊。或壓製成片。
將上述1000片處方量API和除硬脂酸鎂外其他賦形劑投入料斗混合機混勻，採用滾筒壓製機壓成帶狀物，將帶狀物碎成顆粒，加硬脂酸鎂總混10min，中控含量，灌裝膠囊。或壓製成片。
將上述1000片處方量API和賦形劑投入料斗混合機混勻，中控含量，灌裝膠囊。或壓製成素片，包衣，控制包衣增重3%。
處方26-28，1000粒處方量API和賦形劑投入料斗混合機混勻，中控含量，灌裝膠囊。處方29-30，混合後直接壓製成素片，包衣，控制包衣增重3%。
處方31-32，1000粒處方量API和賦形劑投入料斗混合機混勻，中控含量，灌裝膠囊。處方33-34，混合後直
接壓製成素片，包衣，控制包衣增重3%。處方35，將式I化合物和除硬脂酸鎂外其他賦形劑投入料斗混合機混勻，採用滾筒壓製機壓成帶狀物，將帶狀物碎成顆粒，加硬脂酸鎂總混10min，中控含量，壓製成片，包衣，控制包衣增重3%。
將實施例8製備的膠囊採用市售包裝，在40℃±2℃、相對濕度75%±5%條件下，放置6個月，檢測結果見表1。
將式I化合物鹽和潤滑劑外賦形劑進行濕法製粒，乾燥後整粒，加潤滑劑總混10min，中控含量。處方36-38，灌裝膠囊，處方39-41，壓製成片，包衣，控制包衣增重3%。
Claims (16)
- 一種式(I)化合物或其鹽的藥物組合物，其係包括式I化合物或其鹽，以及藥學上可接受的賦形劑作為載體，該等鹽係選自鹽酸鹽或羥乙基磺酸鹽，
- 如申請專利範圍第1項所述的藥物組合物，其中，該等的稀釋劑係選自澱粉、糖粉、糊精、乳糖、預膠化澱粉、磷酸氫鈣、硫酸鈣、碳酸鈣、甘露醇、山梨醇或微晶纖維素中的至少一種。
- 如申請專利範圍第2項所述的藥物組合物，其中，該等的稀釋劑係選自乳糖、微晶纖維素、澱粉或甘露醇中的 至少一種。
- 如申請專利範圍第1項所述的藥物組合物，其中，該等的黏合劑係選自澱粉漿、羥丙甲纖維素、羥丙纖維素、聚維酮、甲基纖維素、羧甲基纖維素鈉或聚乙二醇的至少一種。
- 如申請專利範圍第4項所述的藥物組合物，其中，該等的黏合劑係選自羥丙基纖維素或聚維酮的至少一種。
- 如申請專利範圍第1項所述的藥物組合物，其中，該等的崩解劑係選自交聯羧甲基纖維素鈉、羧甲基澱粉鈉、交聯聚維酮、乾澱粉或低取代羥丙基纖維素中的至少一種。
- 如申請專利範圍第6項所述的藥物組合物，其中，該等的崩解劑係選自交聯聚維酮、羧甲澱粉鈉、交聯羧甲基纖維素鈉中的至少一種。
- 如申請專利範圍第1項所述的藥物組合物，其中，該等潤滑劑係為硬脂酸鎂、硬脂酸、硬脂酸甘油酯、膠態二氧化矽、二氧化矽、滑石粉或山崳酸甘油酯中的至少一種。
- 如申請專利範圍第8項所述的藥物組合物，其中，該等潤滑劑係為硬脂酸、山崳酸甘油酯、膠態二氧化矽中的至少一種。
- 如申請專利範圍第1項所述的藥物組合物，其中，該等表面活性劑係為十二烷基硫酸鈉、吐溫80或泊洛沙姆188。
- 如申請專利範圍第10項所述的藥物組合物，其中，該等表面活性劑係為十二烷基硫酸鈉。
- 一種申請專利範圍第1項所述的式(I)化合物或其鹽的藥物組合物的製備方法，其中，係藉由濕法製粒製備，該等方法包括以下步驟：1)在濕法混合製粒機中預混合式(I)化合物或其鹽與部分賦形劑，獲得預混合物；2)添加製粒液體，將步驟1)的預混合物製粒；3)在流化床乾燥器或乾燥箱中乾燥步驟2)的顆粒；4)任選的，乾燥篩分步驟3)的乾燥的顆粒；5)混合步驟4)的乾燥的顆粒與剩餘賦形劑，獲得最終混合物；6)任選的，藉由合適的膠囊灌裝機灌裝上述步驟5)的混合物，製備膠囊劑；7)任選的，藉由在合適的壓片機上壓製上述步驟5)的混合物，將其壓片，從而製得片芯；8)任選的，用膜包衣對步驟7)的片芯進行薄膜包衣。
- 如申請專利範圍第12項所述的製備方法，其中，該等製粒液體為水。
- 一種申請專利範圍第1項所述的式(I)化合物或其鹽的藥物組合物的製備方法，其中，係藉由乾法製粒完成的，該等方法包括以下步驟：1)在料斗混合機中混合該等式(I)化合物或其鹽和部分賦形劑，獲得預混合物； 2)在合適的滾筒壓製機中壓實步驟1)的混合物；3)藉由合適的研磨或篩分步驟，將步驟2)期間獲得的帶狀物碎成顆粒；4)任選的，在混合機中混合步驟3)和剩餘賦形劑，獲得最終混合物；5)任選的，藉由合適的膠囊灌裝機灌裝上述步驟4)的混合物，製備膠囊劑；6)任選的，藉由在合適的壓片機上壓製上述步驟4)的混合物，將其壓片，從而製得片芯；7)任選的，用膜包衣對步驟6)的片芯進行薄膜包衣。
- 一種申請專利範圍第1項所述的式(I)化合物或其鹽的藥物組合物的製備方法，其中，該等藥物組合物係藉由直接混合的方法製得。
- 如申請專利範圍第14項所述的製備方法，其中，該等方法係包括以下步驟：1)在料斗混合機中混合該等式(I)化合物或其鹽和其他所有賦形劑，獲得混合物；2)任選的，藉由膠囊灌裝機灌裝上述步驟1)的混合物，製備膠囊劑；3)任選的，藉由在合適的壓片機上壓製上述步驟1)的混合物，將其壓片，從而製得片芯；4)任選的，用膜包衣對步驟3)的片芯進行薄膜包衣。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410623810.2A CN105616418A (zh) | 2014-11-07 | 2014-11-07 | 含有细胞周期蛋白抑制剂的药物制剂及其制备方法 |
| CN201410623810.2 | 2014-11-07 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201617082A TW201617082A (zh) | 2016-05-16 |
| TWI704918B true TWI704918B (zh) | 2020-09-21 |
Family
ID=55908611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW104136656A TWI704918B (zh) | 2014-11-07 | 2015-11-06 | 含有細胞周期蛋白抑制劑的藥物製劑及其製備方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20180280392A1 (zh) |
| EP (1) | EP3216450B1 (zh) |
| JP (1) | JP6682739B2 (zh) |
| CN (2) | CN105616418A (zh) |
| TW (1) | TWI704918B (zh) |
| WO (1) | WO2016070834A1 (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10449195B2 (en) | 2016-03-29 | 2019-10-22 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical formulation of palbociclib and a preparation method thereof |
| CN110314148A (zh) * | 2019-05-07 | 2019-10-11 | 安徽金太阳生化药业有限公司 | 一种磷酸氢钙片的制备方法 |
| CN114246841B (zh) * | 2020-09-24 | 2024-02-02 | 南京济群医药科技股份有限公司 | 一种羟乙磺酸哌柏西利的组合物及药物 |
| CN114306245A (zh) | 2020-09-29 | 2022-04-12 | 深圳市药欣生物科技有限公司 | 无定形固体分散体的药物组合物及其制备方法 |
| CN117298115A (zh) * | 2022-11-18 | 2023-12-29 | 轩竹生物科技股份有限公司 | CDKs抑制剂的药物组合物及制备方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050059670A1 (en) * | 2003-07-11 | 2005-03-17 | Pfizer Inc | Isethionate salt of a selective CKD4 inhibitor |
| CN101001857A (zh) * | 2002-01-22 | 2007-07-18 | 沃尼尔·朗伯有限责任公司 | 2－(吡啶－2－基氨基)－吡啶并[2,3－d]嘧啶－7－酮 |
| TW201129386A (en) * | 2009-11-05 | 2011-09-01 | Fmc Corp | Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010007863A1 (en) * | 1998-06-18 | 2001-07-12 | Merck & Co., Inc. | Wet granulation formulation for bisphosphonic acids |
| EP2076249A2 (en) * | 2006-10-27 | 2009-07-08 | FMC Corporation | Dry granulation binders, products, and use thereof |
| RU2619944C2 (ru) * | 2013-02-21 | 2017-05-22 | Пфайзер Инк. | Твердые формы селективного ингибитора CDK4/6 |
| EP3186252A1 (en) * | 2014-08-28 | 2017-07-05 | ratiopharm GmbH | Method of producing palbociclib and pharmaceutical compositions comprising the same |
| SI3302565T1 (sl) * | 2015-06-04 | 2020-02-28 | Pfizer Inc. | Trdne farmacevtske oblike palbocikliba |
| CN104892604B (zh) * | 2015-06-19 | 2016-08-24 | 北京康立生医药技术开发有限公司 | 一种cdk4抑制剂的合成方法 |
| CN105213322A (zh) * | 2015-10-30 | 2016-01-06 | 南京正大天晴制药有限公司 | 一种干法制粒工艺制备的药物组合物 |
-
2014
- 2014-11-07 CN CN201410623810.2A patent/CN105616418A/zh active Pending
-
2015
- 2015-11-06 TW TW104136656A patent/TWI704918B/zh not_active IP Right Cessation
- 2015-11-06 EP EP15857367.5A patent/EP3216450B1/en active Active
- 2015-11-06 JP JP2017521077A patent/JP6682739B2/ja not_active Expired - Fee Related
- 2015-11-06 CN CN201580043546.8A patent/CN106794183B/zh active Active
- 2015-11-06 WO PCT/CN2015/093953 patent/WO2016070834A1/zh active Application Filing
- 2015-11-06 US US15/524,394 patent/US20180280392A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101001857A (zh) * | 2002-01-22 | 2007-07-18 | 沃尼尔·朗伯有限责任公司 | 2－(吡啶－2－基氨基)－吡啶并[2,3－d]嘧啶－7－酮 |
| US20050059670A1 (en) * | 2003-07-11 | 2005-03-17 | Pfizer Inc | Isethionate salt of a selective CKD4 inhibitor |
| TW201129386A (en) * | 2009-11-05 | 2011-09-01 | Fmc Corp | Microcrystalline cellulose and calcium phosphate compositions useful as pharmaceutical excipients |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105616418A (zh) | 2016-06-01 |
| US20180280392A1 (en) | 2018-10-04 |
| EP3216450A8 (en) | 2018-02-07 |
| WO2016070834A1 (zh) | 2016-05-12 |
| CN106794183A (zh) | 2017-05-31 |
| EP3216450A4 (en) | 2018-06-13 |
| TW201617082A (zh) | 2016-05-16 |
| EP3216450B1 (en) | 2021-09-22 |
| JP2017532347A (ja) | 2017-11-02 |
| CN106794183B (zh) | 2021-06-18 |
| JP6682739B2 (ja) | 2020-04-15 |
| EP3216450A1 (en) | 2017-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI704918B (zh) | 含有細胞周期蛋白抑制劑的藥物製劑及其製備方法 | |
| TWI727935B (zh) | 含有細胞週期蛋白抑制劑固體分散體的醫藥組成物及其製備方法 | |
| KR101285008B1 (ko) | 저용량 엔테카비어의 경구투여 제제의 제조방법 | |
| KR101977785B1 (ko) | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 및 그 제조방법 | |
| US20210154194A1 (en) | Ceritinib Formulation | |
| TW201818936A (zh) | 一種吡啶酮類衍生物醫藥組成物及其製備方法 | |
| WO2022062096A1 (zh) | 一种改善羟乙磺酸哌柏西利流动性的工艺方法及组合物 | |
| CN114028400A (zh) | 一种含有细胞周期蛋白激酶抑制剂的药物组合物及其制备方法 | |
| CN106974892A (zh) | 一种含有4‑氨基‑吡咯并三嗪衍生物类激酶抑制剂的药物组合物及其制备方法 | |
| CN114831993A (zh) | 含有wee1抑制剂的药物制剂组合物及其制备方法 | |
| CN107648237B (zh) | 氨基嘧啶类化合物的药物组合物及其制备方法 | |
| KR102136459B1 (ko) | 바제독시펜과 비타민 d를 포함하는 복합제제 | |
| KR101852856B1 (ko) | 비타민 d 또는 그 유도체를 함유하는 과립 및 상기 과립과 라록시펜을 포함하는 복합 캡슐제 | |
| CN117298115A (zh) | CDKs抑制剂的药物组合物及制备方法 | |
| CN115006400A (zh) | 一种含有哌柏西利的药物组合物及其制备方法 | |
| CN115843243A (zh) | 盐酸鲁拉西酮组合物及其制备方法 | |
| CN103860550A (zh) | 左旋多巴/卡比多巴/罗匹尼罗药物制剂 | |
| CN113350350A (zh) | 一种含有盐酸培唑帕尼的药物组合物的制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |